State Ledger
Company profile

Enveric Biosciences, Inc. CIK 890821

Ticker
ENVB (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Cambridge, MA 02142
Fiscal year end
2025 (FY)
Market Data
Close
$1.47
Change
-$0.01
Change %
-0.34%
Volume
800

ENVB · trading date Oct 12, 2026 · previous close $1.48 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$8.77M
Total assets
$5.10M
Total liabilities
—
Stockholders' equity
$4.18M
Cash & equivalents
—
Operating income
-$8.77M
Operating cash flow
-$8.14M
Capital expenditures
—

Fiscal year 2025, via 10-K filed 2026-03-27. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
—
Equity / assets
82.0%
CapEx / revenue
—
Operating cash flow / net income
0.93×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$8.77M $5.10M — $4.18M
2024 — -$9.57M $3.08M — $1.59M
2023 — -$17.29M $4.30M — $1.96M
2022 — -$18.47M $19.55M $4.00M $14.67M
2021 — -$48.98M $26.72M $4.41M $22.31M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-14
Financials filed via
Form 10-K
filed 2026-03-27

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Cambridge, MA 02142
245 FIRST STREET RIVERVIEW II 18TH FLOOR
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 16:04 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Massachusetts — Public Companies